Literature DB >> 27344603

Posterior urethra: Anterior urethra ratio in the evaluation of success following PUV ablation.

R Babu1, S Hariharasudhan2, C Ramesh2.   

Abstract

INTRODUCTION: There are conflicting reports on the criteria with which to determine success following posterior urethral valve (PUV) ablation. The aims of this study were to assess the value of the posterior urethra: anterior urethra ratio (PAR) in predicting successful PUV ablation.
MATERIALS AND METHODS: All neonates and infants with confirmed PUV on voiding cystourethrogram (VCUG) were included. Initial PAR was computed by dividing maximum posterior urethral diameter by anterior urethral diameter. Distances were measured by an on-screen distance measurement tool in the Radiology department, to avoid error. Only oblique images with good voiding phases were used for assessment. All patients underwent cystoscopy and PUV ablation using cold knife. Postoperative VCUG and cystoscopy were performed at 3 months follow-up. Success was defined as cystoscopic resolution of obstruction, in addition to biochemical and radiological improvement, and this was compared with PAR findings. An equal number of age-matched control patients who had a normal VCUG (as a part of evaluation of antenatal hydronephrosis) were also analyzed.
RESULTS: A total of 56 patients (median age 15 days, range 3-250 days) were analyzed between 2013 and 2016. The mean PAR was 1.5 (0.42) in controls and 3.42 (0.75) in those with PUV at diagnosis (P = 0.001). In those with successful PUV ablation (n = 51) the mean PAR was 1.8 (0.21), and in those with residual PUV/stricture (n = 5) the mean PAR was 3.16 (0.54). The difference between these two groups was statistically significant (P = 0.0001). Applying the value of mean + 2 SD of successful PUV ablation, an upper limit of PAR >2.2 was proposed to predict failure. Using this cut-off, 4/7 with PAR >2.2 had confirmed failure, while 48/49 with PAR <2.2 had successful resolution (P = 0.001)
CONCLUSION: Whenever the posterior urethra is more than 2.2 times the diameter of the anterior urethra (PAR >2.2) on repeat VCUG following a PUV ablation, a cystoscopy check is essential to rule out residual PUV/stricture.
Copyright © 2016 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Children; PUV ablation; Posterior urethral valve; Residual valve; Stricture; Voiding cystourethrogram

Mesh:

Year:  2016        PMID: 27344603     DOI: 10.1016/j.jpurol.2016.04.041

Source DB:  PubMed          Journal:  J Pediatr Urol        ISSN: 1477-5131            Impact factor:   1.830


  5 in total

1.  Insight into Posterior Urethral Valve Management.

Authors:  Ramesh Babu; V V S Chandrasekharam
Journal:  J Indian Assoc Pediatr Surg       Date:  2021-03-04

2.  Bladder height width ratio on voiding cystourethrogram as a predictor of future valve bladder in children with posterior urethral valve.

Authors:  Ramesh Babu; Venkata Sai
Journal:  Pediatr Surg Int       Date:  2022-04-13       Impact factor: 1.827

3.  Can the posterior:anterior urethral ratio on voiding cystourethrogram be used as a reliable predictor of successful posterior urethral valve ablation in male children?

Authors:  Zakiyah Gaibie; Nasreen Mahomed; Karen L Petersen; Glenda Moonsamy; Akram A H Bokhari; Ahmed Adam
Journal:  SA J Radiol       Date:  2020-06-09

4.  Correlation of Urethral Ratio and Bladder Wall Thickness with Cystoscopic Findings in Posterior Urethral Valve Patients to Assess Residual Valves.

Authors:  Tanmay Motiwala; Arvind Sinha; Kirtikumar J Rathod; Vivek Manchanda; Taruna Yadav; Avinash Jadhav; Manish Pathak; Rahul Saxena
Journal:  J Indian Assoc Pediatr Surg       Date:  2022-01-11

5.  Role of Urinary Transforming Growth Factor Beta-B1 and Monocyte Chemotactic Protein-1 as Prognostic Biomarkers in Posterior Urethral Valve.

Authors:  Pranay Panigrahi; Sarita Chowdhary; Shyamendra Pratap Sharma; Rakesh Kumar; Neeraj Agarwal; Shiv Prasad Sharma
Journal:  J Indian Assoc Pediatr Surg       Date:  2020-06-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.